CClinicalTrials.gg
CompletedNCT05778201Updated Jun 15, 2026

To Study the Effects of Baby Drink on Vision Care

An Early Phase 1 interventional study of Baby Drink group in Myopia, sponsored by China Medical University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by China Medical University Hospital · Early Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 5 months ago, and no results have been posted to the registry.
Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Baby Drink is a formula based on lutein, mixed with blueberry fermented liquid, vitamins and minerals. Lutein is an effective antioxidant to prevent retinal damage caused by blue light, but it cannot be produced in the human body and depends on dietary intake. Blueberry fermented liquid is rich in polyphenolic compounds with excellent antioxidant capacity and the potential to reduce oxidative damage to eye cells caused by ultraviolet rays. With the prevalence of 3C products, myopia patients are increasing year by year in various regions, and suffer from eye diseases or vision loss with different degrees of complications. In this study, the subjects were provided with Baby Drink and tracked the degree of visual fatigue by regular questionnaires, and measured for visual acuity, axial length and diopter. The aim of this study is to investigate the protection of Baby Drink on visual acuity and visual fatigue.

Read the detailed description
  1. Visual acuity measurement: Snellen's Chart was used to measure visual acuity.
  2. Refractive examination: Measure binocular refraction with Open Field computer refractor (Shin-Nippon Nvision K5001 Wide View).
  3. Measuring the axial length of the eye: Use the multifunctional optical eyeball length measuring instrument (Lenstar) to measure the distance from the instrument to the optical paths such as the cornea, lens, and retina, and then convert to the axial length of the eye.
  4. Corneal radian measurement: Use a keratometer (Bausch \& Lomb Keratometer) to measure the corneal radian and curvature, and estimate the degree of corneal astigmatism.
  5. Visual fatigue questionnaire survey: A visual fatigue scale questionnaire was designed using Ocular Surface Disease Index (OSDI) and Computer Vision Syndrome (CVS).
02

Conditions studied

  • Myopia

Browse trials for

03

In context

Myopia

983 studies on the registry are indexed under Myopia; 209 are open to participants now.

This study's enrollment of 20 is below the median of 80 across 782 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Adults aged 20 or over
  2. Willing to participate in this study and sign the subject's consent form
  3. Myopia less than 700 degrees

Exclusion criteria

Exclusion Criteria:

  1. Have consumed related eye care products in past 3 months
  2. Those who have eye infection in the past 3 months
  3. People who have been diagnosed with any eye diseases in past 3 months
  4. Those who are allergic to cicadae
05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Baby Drink group

    1 package/ day for 1 month

    Biological: Baby Drink group

Interventions

  • BiologicalBaby Drink group

    1 packge (20 ml)/ day for 1 month

06

What researchers measure

Primary outcomes

  1. Eye fatigue questionnaire

    1. Eye fatigue were evaluated according to The Ocular Surface Disease Index (OSDI) introduced in 1997 by the Outcomes Research Group (Allergan Inc., Irvine, CA). 2. Content including: (1) Eye swelling, (2) Eye soreness, (3) Photophobia, (4) Blurred vision, (5) Dry eye, (6) Foreign body sensation, (7) Tearing, (8) General discomfort related to eye fatigue. 3. Scores are expressed on a scale of 0-3. 0 = No symptoms , 1 = Occasionally (≤1 time/day), 2 = Sometimes (1-3 times/day), 3 = Frequently (\>3 times/day), a low score means less visual fatigue and better eye quality.

    Time frame: 1 month

  2. Best vision test

    1. Visual acuity was tested with the Snellen Eye Test Chart and recorded with the score proposed by Snellen. 2. Subjects were asked to stand 20 feet away to observe the snellen E-chart and record the smallest visual mark. 3. Recording method: 20/20 (1.0) is defined as normal vision, lower than this score indicates that the subject has ametropia, and higher than this indicates that the subject's vision is higher than the general standard

    Time frame: 1 month

07

Study locations

1 site
  • Asia university
    Taichung, 413, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05778201
Lead sponsor
China Medical University Hospital
Responsible party
Hui Wen Lin (Clinical Professor, China Medical University Hospital) — Principal investigator
First posted
Mar 21, 2023
Start date
Mar 18, 2023
Primary completion
Apr 19, 2023
Completion
Aug 31, 2023
Last update
Jun 15, 2026

Study contacts

Hui Wen Lin, ph.D
principal investigator · Asia University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion